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Abstract
The Leiden Longevity Study consists of families that express extended survival across generations, decreased morbidity in
middle-age, and beneficial metabolic profiles. To identify which pathways drive this complex phenotype of familial
longevity and healthy aging, we performed a genome-wide gene expression study within this cohort to screen for mRNAs
whose expression changes with age and associates with longevity. We first compared gene expression profiles from whole
blood samples between 50 nonagenarians and 50 middle-aged controls, resulting in identification of 2,953 probes that
associated with age. Next, we determined which of these probes associated with longevity by comparing the offspring of
the nonagenarians (50 subjects) and the middle-aged controls. The expression of 360 probes was found to change
differentially with age in members of the long-lived families. In a RT-qPCR replication experiment utilizing 312 controls, 332
offspring and 79 nonagenarians, we confirmed a nonagenarian specific expression profile for 21 genes out of 25 tested.
Since only some of the offspring will have inherited the beneficial longevity profile from their long-lived parents, the
contrast between offspring and controls is expected to be weak. Despite this dilution of the longevity effects, reduced
expression levels of two genes, ASF1A and IL7R, involved in maintenance of chromatin structure and the immune system,
associated with familial longevity already in middle-age. The size of this association increased when controls were compared
to a subfraction of the offspring that had the highest probability to age healthily and become long-lived according to
beneficial metabolic parameters. In conclusion, an ‘‘aging-signature’’ formed of 21 genes was identified, of which reduced
expression of ASF1A and IL7R marked familial longevity already in middle-age. This indicates that expression changes of
genes involved in metabolism, epigenetic control and immune function occur as a function of age, and some of these, like
ASF1A and IL7R, represent early features of familial longevity and healthy ageing.
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Introduction
Nonagenarians and centenarians delay or escape age-related
diseases [1], their first degree family members have a life-long
survival advantage [2,3] and their middle-aged offspring have a
decreased prevalence of and mortality from coronary heart
disease, type 2 diabetes, and cancer [4,5]. In addition, the
offspring of long-lived individuals have beneficial physiological
characteristics for lipid and lipoprotein particle profiles [6,7],
glucose metabolism and insulin sensitivity [8,9]. However, they do
not differ from controls with respect to body mass index, serum
IGF-1 levels, height and lifestyle factors such as physical activity
levels and smoking behavior [10,11]. Although familial longevity is
a complex phenotype, identifying transcriptional targets that may
contribute to the physiological benefits observed in long-lived
families will increase our understanding of which pathways can
influence susceptibility to and protection from age-related disease.
Previous studies have investigated whether there are gene
expression changes that occur with age in brain, lymphocyte,
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genes were found not only to change with age but also to reflect
the biological function of the source organs [18,19]. These studies
have demonstrated that gene expression levels are not only
markers of chronological age but also of tissue function. However,
these studies cannot discriminate between genes showing expres-
sion changes in mid-life that may contribute to the aging process,
from those showing expression changes later in life as a
consequence of the aging process.
Here we report transcriptional profiling of whole blood samples
from participants of the Leiden Longevity Study which is based in
the Netherlands and comprises nonagenarian sibling pairs, their
middle-aged offspring and the partners of the offspring as
population controls. A comparison of gene expression profiles
between the nonagenarian siblings and controls identified profiles
that associate with age. The subsequent comparison of the middle-
aged offspring and the controls enabled the identification of genes
that mark the propensity to become long-lived in middle-age.
Results
Whole genome microarrays and analysis design
Gene expression profiles were generated from 150 whole blood
total RNA samples collected from 50 families belonging to the
Leiden Longevity Study (LLS). From each family, one nonage-
narian sibling, one of their offspring and the offspring’s partner
(Table 1) were profiled. We identified 47,209 probes (88% of the
total number of probes) which were expressed in at least 10% of
the samples. Of these, 45,164 probes (containing at least 17,896
unique genes) could be mapped to a chromosomal position and
were, therefore, used for further analyses.
The explorative analysis is divided in two parts (Figure 1). The
first analysis focused on the comparison between the long-lived
nonagenarians and the population controls (the partners of the
offspring). Using this design we aimed to find genes whose
expression changed with increasing age and among these, those
that were differentially expressed in long-lived families. In the
second analysis we investigated which of the differentially
expressed genes emerging from the first analysis were already
differentially expressed between long-lived family members and
controls in middle-age. Therefore we compared the offspring to
the controls for mean gene expression differences and also for the
interaction between the two groups with age to identify genes
whose expression changed differentially with age between
offspring and controls. Following the explorative analysis, we
performed replication analyses in an extended group of the LLS
using RT-qPCR on a selected subset of the differentially expressed
genes.
Differential gene expression associating with age
To investigate the differences in gene expression levels between
the nonagenarian subjects and the middle-aged controls a linear
regression model was applied to the probe data. With adjustments
for gender and batch effects (Model 1, see Materials and Methods)
2,953 probes (of which 1,853 represented known genes) were
found to be differentially expressed at a false discovery rate (FDR)
of 0.05 (Figure 2 and Supplementary Table S1). The expression
levels of 1,046 probes were increased and 1,907 decreased in the
nonagenarians compared to the younger controls. The probe that
associated with age with the highest significance (FDR adjusted p-
value=5610
210) is located in the leucine rich repeat neuronal 3
gene (LRRN3, 7q31.1) and showed a 3.1-fold decreased expression
in nonagenarians, which was also the largest difference in
expression level between the two groups. The largest increase in
expression level was 2-fold for a probe targeting the interferon,
alpha-inducible protein 27 isoform (IFI27, 14q32.13) gene locus.
This probe could also target SYTL1, but since the levels of a
specific probe for SYTL1 did not correlate with the IFI27 probe
(Pearson correlation=20.14), while a unique probe for IFI27 did
correlate (Pearson correlation=0.96), the result suggests that IFI27
mRNA is responsible for the association. Average expression levels
of the 2,953 probes show a distribution over the whole range of
measured intensities (Supplementary Figure S1) and 89.5% of
these probes were detected in $95% of the samples.
If a group of differentially expressed genes act in the same
pathway or biological function this could lead to an additive or even
synergistic effect on cellular function. Furthermore, the interpreta-
tion of transcriptional data in a pathway context is a more robust
signal to noise measurement. The Gene Ontology (GO) consortium
[20] provides structured vocabularies and classification of genes,
covering several domains of molecular and cellular biology. Hence,
GO terms were tested for differences between nonagenarians and
controls using the Globaltest methodology [21,22]. Globaltest
determines whether the expression pattern of genes within a set as a
whole is associated with an outcome, in this case being
nonagenarian or not, without testing single probes. We assayed
1,808 GO gene sets, representing groups of genes closely related in
their biological functionor process,containingatleast 10probesper
GO term, again using Model 1. The Globaltest showed that 109
GO term gene sets were significantly differentially expressed
between nonagenarians and controls at a family-wise error rate
(FWER) of #0.05 (Supplementary Table S2). FWER is used
because the gene sets for GO terms are partly overlapping and
therefore not independent. These 109 GO terms include 73
biological processes, 31 molecular functions and 5 cellular
components. The biological processes identified under the higher
level GO classifications were ‘lymphocyte activation’, ‘anatomical
structure development’, ‘response to stimulus’ (including ‘immune
response’), ‘regulation of gene expression’, and ‘regulation of signal
transduction’. For the molecular functions list, pathways involved in
protein binding were the most abundant.
Differential gene expression in middle-age associating
with longevity
The nonagenarian participants in the LLS each exhibit the
longevity phenotype and their offspring, as a group, carry the
potential to become long-lived as demonstrated by beneficial
Table 1. Description of the participants of the LLS in the
microarray and validation population.
Controls Offspring Nonagenarians
A Microarray experiment
N5 0 5 0 5 0
Males/females (%
males)
24/26 (48%) 25/25 (50%) 26/24 (52%)
Mean age in years
(range)
61.9 (43.7–78.8) 60.8 (42.8–74.8) 93.4 (89.3–102.2)
B RT-qPCR experiment
N 312 332 79
Males/females (%
males)
143/169 (45.8%) 190/142 (57.2%) 34/45 (43.0%)
Mean age in years
(range)
61.3 (40.9–81.4) 61.3 (33.6–78.3) 94.1 (89.0–101.2)
doi:10.1371/journal.pone.0027759.t001
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generation [23–25]. The physiological differences between
offspring and controls are small since not all individual offspring
may have inherited the longevity trait. To distinguish which of the
2,953 probes that associated with age also reflect familial longevity
already in middle-age, gene expression levels were compared
between the 50 offspring of the nonagenarians and the 50 controls
(Table 1). In a linear regression model adjusting for age, gender
and batch effects (Model 2, see Materials and Methods), we
observed no significant differences in the average expression levels
between the offspring and controls. Next, we investigated
differential expression changes as a function of age between the
offspring and the controls by testing the interaction between group
and age (Model 3, see Materials and Methods). Differential
expression (FDR#0.1) between offspring and controls across the
age-range (43–79 years) was observed for 360 probes, representing
244 unique genes (Supplementary Table S3). Of these probes, 359
had a fold change below 1, indicating that expression levels had
either a weaker increase with age or a stronger decrease with age
in the offspring compared to controls. These age-related
expression differences may represent early characteristics of
human longevity.
The most significant differentially expressed probe (FDR
adjusted p-value=0.050, 1.6-fold decrease every ten years)
corresponded to the zinc finger protein 331 gene (ZNF331,
19q13.33) whereas the largest decrease in expression level was for
a probe targeting a mRNA at chromosome 1q43 (no known
corresponding gene); this had a 2.1-fold decreased expression in
offspring every ten years relative to controls. The only probe that
demonstrated a significant increase in expression with age in the
offspring (a 1.3-fold change every ten years) targeted an EST at
20q13.2 (no known corresponding gene, NCBI Build 36). We
Figure 1. Flowchart of gene expression analyses. The order of analyses is shown for the explorative analysis (top half of the figure) and the
replication analysis (bottom half of the figure). The probes/genes are depicted in the boxes and to the left thereof are the techniques or analyses
used.
doi:10.1371/journal.pone.0027759.g001
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for LRRN3 and IFI27, which had the most extreme changes with
age in the first analysis in which nonagenarians and controls were
compared.
To investigate differential expression changes with age in a set
of genes acting in the same pathway or having the same function,
we implemented Model 3 in GlobalAncova [26]; a method similar
to the Globaltest for GO terms but additionally suited for models
including interaction terms. The GO biological process that was
most prominent among the longevity associated gene expression
profile was the Rho protein signal transduction pathway
(GO:0007266) (FWER=0.079).
Extensive replication study
To replicate our results we measured the expression levels of a
subset of genes via RT-qPCR in 79 nonagenarians, 332 offspring
and 312 controls (Table 1 and Materials and Methods). We first
selected two genes on the basis of their effect size and significance
in the analysis between nonagenarians and controls (i.e. LRRN3
and IFI27) and the gene different between offspring and controls
(i.e. ZNF331). We added 22 genes that were differentially
expressed in the offspring compared to controls which additionally
associated with the concept ‘‘cell aging’’ in literature using the text-
mining tool Anni 2.0 [27], http://biosemantics.org/anni/. In total
25 genes (Figure 1), including the WRN progeria gene, the MYC
cancer gene and the longevity MTOR (also known as FRAP1) gene,
were selected for replication analyses.
As replication of the first analysis, the comparison between
nonagenarians and controls, the expression of 21 out of 25 genes
was in concordance with the observations in the microarray
dataset and hence the RT-qPCR results confirmed the microarray
findings (Table 2). LRRN3 again showed the largest significant
Figure 2. Expression profiles of 2,953 probes that differed between nonagenarians and middle-aged controls. Expression intensities of
the 2,953 probes were analyzed by one-dimensional hierarchical clustering. Each probe is represented by a row; each subject by a column. Samples
are organized left to right by increasing age which is indicated for a few individuals for reference. The largest cluster of probes exhibits reduced
expression (transition from red to blue), and another cluster exhibits increased expression (transition from blue to red) in nonagenarians comparedt o
controls. Mean centered expression values of probes are displayed according to the color scale in which red represents above average expression
levels and blue below average expression levels. Fold changes of individual probes are given in Supplementary Table S1.
doi:10.1371/journal.pone.0027759.g002
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largest increased expression. The analysis to test for replication of
the novel samples only (58 nonagenarians and 281controls)
resulted in the same observations (Supplementary Table S4).
To identify longevity associated genes in middle-age, we
replicated the second analysis by comparing the mean expression
levels of 23 genes between the offspring of the nonagenarians and
the controls (Model 2, see Materials & Methods). We excluded
LRRN3 and IFI27 from this analysis since expression of these two
genes was not different between offspring and controls in the
microarray dataset. Two genes showed significant differential
expression after Bonferroni correction for multiple testing: ASF1A
and IL7R (Table 2, p,0.0022). These two genes showed a
significant decrease in expression in samples from the long-lived
families compared to controls, in concordance with the microarray
results.
Analysis of healthy offspring
We noticed that the effect sizes of the differential expressed
genes in the comparison between offspring and controls were
small. Since the offspring are composed of individuals who carry
the longevity trait and those that do not, the detectable effect of the
longevity trait is diluted in the comparison between offspring and
controls. We hypothesize that the effect of the longevity trait will
increase if we compare the same controls to a subfraction of
offspring with the highest probability to age healthily and become
long-lived. Therefore we selected the offspring with the most
beneficial metabolic profile.
Offspring of long-lived parents exhibit as a group at least six
beneficial serum characteristics including: low levels of glucose
[28,29], triglycerides [30], total cholesterol over HDL cholesterol
ratio [31,32], free triiodothyronine [33], and large low-density
lipoprotein (LDL) particles [34], complemented by high adipo-
nectin [35]. The beneficial metabolic profile is also reflected by the
lower Framingham risk scores [36] which indicates a lower risk of
cardiovascular disease over the course of 10 years.
We selected a subfraction of the offspring, consisting of the 5%
beneficial tail of the distribution of each metabolic parameter,
separately for men and women, resulting in 78 offspring which we
consider the best proxy for the true long-lived cases. For these
Table 2. RT-qPCR results.
Nonagenarians vs. controls Offspring vs. controls
N= 79 312 332 312
Gene name Assay FC p FC p
Top genes
1 IFI27 Hs01086373_g1 1.41 2.6610
24 NA NA
2 LRRN3 Hs00539582_s1 0.56 ,10
26 NA NA
3 ZNF331 Hs00218578_m1 0.93 1.0610
24 0.99 0.574
Cell aging associated genes
4 ADAMTS5 Hs00199841_m1 1.01 0.008 1.00 0.872
5 ASF1A Hs01011627_m1 0.85 ,10
26 0.88 0.002
6 CCR6 Hs01890706_s1 0.68 ,10
26 1.06 0.265
7 CD248 Hs00535586_s1 .10 0.322 1.04 0.736
8 CDK6 Hs00608037_m1 0.95 0.053 0.95 0.015
9 ENO2 Hs00157360_m1 0.99 ,10
26 0.99 0.044
10 FLT3LG Hs00181740_m1 0.25 0.029 0.63 0.202
11 HK3 Hs01092843_g1 1.17 ,10
26 1.00 0.929
12 IL7R Hs00902338_g1 0.76 ,10
26 0.89 0.001
13 LEF1 AI6Q1P7 0.64 ,10
26 0.97 0.565
14 MLLT3 Hs00971090_m1 0.80 ,10
26 0.95 0.087
15 MTOR (FRAP1) Hs00234508_m1 0.97 6.0610
26 0.99 0.337
16 MYC Hs00153408_m1 0.78 ,10
26 0.98 0.547
17 NOLC1 Hs01102319_g1 0.89 1.0610
26 0.95 0.082
18 NR3C2 Hs00230906_m1 0.78 ,10
26 0.95 0.059
19 RUVBL2 AI7ZZWF 0.79 6.0610
25 1.07 0.469
20 SIDT1 Hs00214475_m1 0.70 5.0610
26 0.91 0.301
21 SMAD3 Hs00706299_s1 0.87 ,10
26 0.99 0.825
22 SMYD5 Hs00300181_m1 0.93 ,10
26 0.98 0.229
23 TCF12 Hs00918972_m1 0.90 ,10
26 0.97 0.127
24 TCF4 Hs00972428_g1 0.88 1.5610
25 1.01 0.872
25 WRN Hs02561119_s1 0.76 ,10
26 1.02 0.791
FC: fold change between groups; a FC above 1 indicates an increase in expression and a FC below 1 indicates a decrease in expression compared to the controls.
p: unadjusted p values. Bold indicate p values are below the significant level of 0.05 after Bonferroni correction for multiple testing (threshold p=0.002).
doi:10.1371/journal.pone.0027759.t002
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of 312 controls: this comparison resulted respectively in a 5.0%
and 1.2% additional decrease of mean gene expression relative to
the effect observed in the comparison between all offspring and
controls (Table 3).
Discussion
We have identified a transcriptional profile of 244 genes that
represent a potential ‘‘longevity-signature’’. In an extensive
biological replication study of nonagenarians, middle-aged off-
spring and controls, we focused on a subset of 25 genes in RT-
PCR experiments. An ‘‘aging-signature’’ was formed by the
expression pattern of 21 genes. Two genes, ASF1A and IL7R,
represented a ‘‘longevity-signature’’ since members of long-lived
families expressed at middle-age a 1.14-fold and 1.12-fold lower
level of these genes compared to controls respectively. The effect
size of this association with longevity was stronger for offspring of
nonagenarians with a beneficial metabolic profile characterized by
6 serum parameters and the Framingham Risk Score, which we
considered to be the best proxy for the true long-lived case group.
The decreased expression of these two genes is therefore likely to
mark metabolic health and it might precede or even contribute to
human longevity. ASF1A is a histone chaperone that is important
in the remodeling of chromatin structure during replication, DNA
repair, and cellular senescence [37–39]. Interestingly, histone
acetylation is among the processes regulated by signaling through
the IL7 receptor, which is required for development and
maintenance of the immune system [40]. Our results may point
at the importance of interactions between immune response,
metabolic state, and epigenetic control for human aging and
longevity.
The genome-wide expression analysis between nonagenarians
and controls resulted in the identification of 2,953 probes
associated with age. RT-qPCR replication experiments with a
large sample size resulted in replication of 21 out of 25 genes
identified by the microarray analysis as differentially expressed
with age. Five of these genes (LRRN3, ZNF331, ASF1A, MLLT3
and SIDT1) have previously been reported to associate with age in
a microarray study of T cell mRNA [41], although this study had a
relatively small number of samples (25 male subjects). The largest
age-related effects observed in our study were for the IFI27 and
LRRN3 genes. IFI27 encodes interferon alpha-inducible protein 27
whose biological function is currently unknown. Leucine rich
repeat neuronal 3 (LRRN3) is mainly involved in activation of
MAPK activity and endocytosis [42] and, further supporting our
findings, also showed the largest age-related decrease in expression
in a large study on lymphocytes [16]. This ‘‘aging-signature’’
included decreased expression of several well-known genes
involved in aging and lifespan, like MYC, WRN and MTOR. The
MYC protein is a transcription factor that regulates transcription
of specific target genes and overexpression of the MYC gene has
been associated with a variety of cancers [43–45]. Defects in the
WRN gene cause the Werner progeria syndrome, an autosomal
recessive disorder characterized by premature aging and genetic
variation in or near this gene have been associated with several
age-related diseases and survival [46–49]. The MTOR gene
encodes a serine/threonine kinase and its downregulation is
associated with extended lifespan in model organisms [50–52] and
elevated mTOR activity has been implicated in different forms of
human cancer [reviewed in 53,54]. We conclude from our data
that, from all significantly differentially expressed genes at least 21
genes distinguish nonagenarians from middle-aged controls. In
addition, our study is the first to include an extensive biological
replication sample set validating these results.
The main cellular pathways that changed with age in the
microarray dataset were ‘response to stimulus’ (including ‘immune
response’ and ‘response to stress’), ‘signal transduction’, ‘gene
expression’ and ‘protein binding’. These GO terms have
previously been found to associate with aging, suggesting that
these are systemic age-related processes. The only pathway that
associated with longevity at middle-age in the offspring-control
comparison was the ‘Rho protein signal transduction’ pathway,
which is part of the GO term ‘signal transduction’. The Rho
family of GTPases are small GTPases that regulate a wide variety
of processes in the cell including growth, cytoskeletal organization,
transcription and lipid metabolism [55,56]. Rho signaling is
regulated by the mTOR complex 2, a part of the mTOR pathway
which is shown to influence lifespan and health. All associated
pathways are general processes, indicating that regulation of the
system seem to be an important process involved in aging and
longevity.
Research into human familial longevity and healthy ageing is
complex in the sense that there are no controls from the same birth
cohort to compare to long-lived persons since such controls would
have died twenty years ago. We investigated offspring as a proxy
for the nonagenarian case group since these can be compared to
controls from the same birth cohort. However, in the offspring the
longevity phenotype will undoubtedly be diluted as compared to
the nonagenarians, since only a part of the offspring will become
long-lived and a part will age comparable to controls. The
consequence of the dilution of the longevity cases is that effect sizes
are underestimated. Indeed the effect size of the association with
longevity increased when the healthiest offspring was compared to
the controls. Future follow-up data on age of death will reveal
which offspring carries the longevity phenotype.
In this study we investigated expression profiles in whole blood
samples of participants because blood is an easily accessible tissue.
This allows us to investigate the large sample sizes required to
detect small effect sizes. An advantage of using blood compared to
other tissues is that cell subsets can easily be measured and used to
select samples or used as covariates in analyses whereas different
cell subsets present in other tissues are difficult to quantify and can
not be taken into account in any analyses. In our microarray study
we selected samples from offspring and controls with similar cell
counts. Furthermore, since aging affects the whole organism and
since blood is in contact with all tissues, blood may reflect in part
the physical health of the whole body. Disease state is mirrored by
Table 3. Gene expression levels of ASF1A and IL7R in all as
well as subfraction of offspring compared to controls.
ASF1A IL7R
n Mean p Mean p
Controls All 312 1.85 6.18
Offspring All 332 1.65 0.002
2 5.98 0.001
2
Subfraction
1 78 1.57 0.009
3 5.91 0.010
3
Mean: relative expression in fold change to reference value.
1: subfraction of offspring most probable to age healthily (for more details, see
Materials and Methods),
2: p value of comparison between controls and all offspring,
3: p value of comparison between controls and subfraction of offspring (best
5% men and women per parameter taken together). Bold indicated p values
are below the significant level of 0.05 after Bonferroni correction for multiple
testing.
doi:10.1371/journal.pone.0027759.t003
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least partial overlap with expression profiles in other tissues [58].
Thus, although tissue-specific effects will undoubtedly be missed,
investigating blood is valuable and practical for researching
human aging.
In conclusion, we identified a transcriptional signature in whole
blood consisting of 21 genes that repeatedly differentiated between
nonagenarians and middle-aged controls. The expression level of
two of these genes, ASF1A and IL7R marked familial longevity
already in middle-age and the effect size was enhanced in the
subset of longevity family members with a beneficial metabolic
marker profile. Functional and longitudinal studies are necessary
to establish which of these genes are true biomarkers for healthy
ageing and which contribute causally to this trait. Our findings
illustrate that gene expression changes occurring as a function of
age may partly represent early detectable features of human
longevity and healthy ageing.
Materials and Methods
Study population
The individuals investigated in this study are participants of the
Leiden Longevity Study. The families participating in this study
have at least two siblings with a minimum age for men of 89 years
and for women of 91 years [59]. The offspring of these long-lived
individuals, who have an increased potential to become long-lived
individuals, were also included. In addition, the partners of the
offspring were included as population controls of similar age and
environmental exposures as the offspring, and as a young control
group for the nonagenarian siblings. Blood samples were taken
from all the participants. The Leiden Longevity Study was
approved by the medical ethical committee of the Leiden
University Medical Centre and all participants gave written
informed consent.
Sample collection and RNA preparation
One long-lived sibling, one of their offspring and the partner of
the offspring were selected from 50 families for the current study
(Table 1). These trios were randomly selected, but in such a way
that age and gender were balanced between the groups and the
age range for the offspring and partners was as large as possible.
Additionally, individuals with outlying cell counts (beyond 3 SDs
below or above the standard error of the mean) were excluded.
From the 150 selected non-fasted individuals, peripheral blood was
harvested using PAXgene
TM tubes (Qiagen, Venlo, The Nether-
lands). The tubes were frozen and kept at 220uC for ,3–5 years.
After thawing at room temperature for at least 2 hours, total RNA
was extracted from the approximately 2.5 ml of peripheral blood
in each tube following the manufacturer’s recommended protocol
(PAXgene Blood RNA Kit Handbook, Qiagen, Venlo, The
Netherlands). The quality and integrity of the total RNA was
evaluated on the 2100 Bioanalyzer (Agilent Technologies,
Amstelveen, The Netherlands) and the concentration was
measured using a NanoDrop spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). Quality criteria included
a 28S/18S ratio as measured by the Bioanalyzer of at least 1.2,
and a total RNA yield of at least 3 mg.
Oligonucleotide microarrays
The 150 samples that met the RNA quality criteria were
hybridized onto 54k CodeLink Human Whole Genome Bioarrays
(GE Healthcare, Bucks, UK, cat. No. 300026, currently of
Applied Microarrays). cDNA synthesis, amplification, biotin
labeling and hybridization onto the microarrays were performed
according to the manufacturer’s instructions using the Codelink
iExpress reagent kit (cat. No. 67601000). The slides were scanned
with a MicroArray Scanner G2505B scanner (Agilent Technolo-
gies, South Queensferry, UK) and the image was quantified with
the CodeLink Expression software (version 4.2).
Microarray data pre-processing
Raw intensities were background subtracted, set to 0.5 when
results were negative and normalized using the Cyclic Loess
method in the Codelink software package [60] of the Bioconductor
R software [61] (http://www.bioconductor.org). After normaliza-
tion, we used log2-transformed expression intensities for all
subsequent analyses. Raw and normalized microarray data are
stored in the GEO online database record GSE16717 in
compliance to MIAME guidelines. A principal component analysis
(PCA) was performed on all samples (GeneSpring software,
Agilent Technologies, South Queensferry, UK) and hybridization
date was identified as a confounding factor causing a deviation in
the data, which was attributed to a scanner maintenance check
during the measurements of the samples (data not shown).
Therefore, all subsequent analyses were adjusted for hybridization
date coded as the 14 days of hybridization as categorical variable,
which was sufficient to adjust for this technically induced variation.
Since samples were randomly hybridized, no confounding with
group was present. None of the other tested parameters, like RNA
quality, isolation date and time of blood draw appeared to be a
significant confounder of the expression data.
Probe annotation and filtering
The 54,243 probes on the CodeLink Bioarray were newly
annotated to Entrez Gene ID’s and GO identifiers in two steps.
First, all probe sequences were mapped to Unigene and dbEst
sequences with BLAT while allowing for, at most, one mismatch-
ing nucleotide. Subsequently, all Probe to Unigene annotations
were transformed to probe to Entrez Gene ID and probe to GO
ID annotations using Entrez Gene-to-Unigene and Entrez Gene-
to-GO ID mappings available on the ftp server of NCBI. Probe-to-
EST annotations were treated in a similar way, except that ESTs
were first mapped to RefSeq Gene IDs by aligning ESTs to
RefSeq exons using galaxy and the genomic alignments of ESTs
and RefSeq genes from UCSC (hg18). All EST to RefSeq
mappings with a sequence similarity .95% were maintained for
further mappings of ESTs-to-Entrez Gene IDs using the Entrez
Gene-to-RefSeq Gene ID mappings available at NCBI. All
information used was downloaded in October 2008, using versions
NCBI Build 36.1 or UCSC hg18.
Probes without a ‘‘Good’’ flag indicating that the mRNA is
detected, as determined by the CodeLink Expression software, in
at least 10% of the samples (7,034 probes) and/or probes without
at least a known chromosome band location according to the new
annotation (an additional 2,045) were excluded from the analysis,
resulting in 45,164 remaining probes.
Single gene analysis
All single gene analyses were performed using the Limma
(Linear models for microarray data) package in R [62,63]. To
determine changes in expression levels of each probe with age, we
used the following linear regression model:
Yij~b0jzb1jGroupizb2jGenderizb3jHybizeij ð1Þ
where Yij is the base 2 logarithm of the expression level of probe j in
sample i, Groupi is the group (0 for control or 1 for long-lived
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to the gender of the ith sample (0 for male, or 1 for female), Hybi is
the categorical term of hybridization day on which the sample i was
measured and eij represents an error term. The coefficients b1j
represents by how much gene expression increases between the
groups, b2j represents the change in expression for a female in
comparison with a male sample, b3j represents the change of
expression across hybridization dates, and b0j represents the
baseline regression level of the probe, for male control samples on
the first hybridization date. Resulting p-values were adjusted for
multiple testing using Benjamini and Hochberg’s False Discovery
Rate (FDR) method [64]. One-dimensional hierarchical clustering
of probes was performed using GeneSpring (version GX 7.3.1) gene
tree clustering, using Pearson correlation and average linkage.
To find longevity-related differences between offspring and
controls, the following model was used:
Yij~b0jzb1jGroupizb2jAgeizb3jGenderizb4jHybizeij ð2Þ
where Groupi corresponds to the offspring/control status of the ith
sample (0 for control, 1 for offspring) and b1j is the change of
expression with group status. For each probe j, we determined the
coefficient with respect to group status (b1j).
To test differences in biological aging rate in offspring and
controls, we used the following model:
Yij~b0jzb1jGroupizb2jAgeizb3jGenderizb4jGroupi|Agei
zb5jAgei|Genderizb6jGroupi|Genderizb7jHybizeij
ð3Þ
where Groupi*Agei corresponds to the slope of expression with age
of the jth probe set for offspring or controls, Agei*Genderi
corresponds to the slope of expression with age of the jth probe
set for males or females, Groupi*Genderi indicates the interaction of
group and gender of the jth probe set for the ith sample, b4j
represents the change of expression with age for offspring in
comparison to control, b5j represents the change of expression with
age for a female in comparison with a male sample, b6j represents
the change of expression with gender between offspring and
controls. The interaction between group and offspring in
comparison to control (b2j for the intercept, b4j for the other
groups) was determined and resulting p-values were corrected for
multiple testing using the FDR method.
Pathway analysis
The Globaltest methodology was designed to determine whether
the common expression pattern of genes within a pre-defined set is
significantly related to clinical outcome [21,65,66]. A generalized
linear model is used to estimate a ‘‘Q-statistic’’ for each gene set,
which describes the correlation between gene expression profiles,X,
and clinical outcomes, Y. The Q-statistic for a gene set is the
average of the Q-statistics for each gene in the set. The Globaltest
method was used to perform pathway analysis on Model 1.
When performing pathway analysis on Model 3 we used
GlobalAncova, which is a method similar to Globaltest suited for
models including interaction terms [67,68]. Resulting p-values
from both methods were corrected for multiple testing using
Holm’s procedure for controlling the Family-Wise Error Rate
(FWER) method [69].
RT-qPCR
To confirm the accuracy of the measured expression profiles, we
compared the expression level of 25 probes from the CodeLink
Bioarrays with corresponding TaqmanH assay (Applied Biosys-
tems, Table 2). Samples included 18 nonagenarians, 16 offspring
and 21 controls that have been measured on the microarray and
additional novel replication samples of randomly chosen 61
nonagenarians, 316 offspring and 291 controls. Reverse transcrip-
tion was performed by using total RNA from blood of in total 723
samples, excluding individuals with outlying cell counts (outside
3SD of the mean), which passed QC and processed with the First
Strand cDNA Synthesis Kit according to the manufacturer’s
protocol (Roche Applied Science). cDNA was amplified using the
DNA Engine TetradH 2 Peltier Thermal Cycler (Bio-Rad). qPCR
was then performed with the TaqmanH method using the
Biomark
TM 48.48 and 96.96 Dynamic Arrays (Fluidigm). Relative
gene expressions of the BioMark
TM Array data were calculated by
using the 2
2DDCt method, in which Ct indicates cycle threshold,
the fractional cycle number where the fluorescent signal reaches
detection threshold [70]. YKT6 was used as internal control and
commercially available human total reference RNA (Clontech
Laboratories, Mountain View, CA, USA) as reference RNA.
Differences in expression level between long-lived siblings, their
offspring and the partners of their offspring were assessed using
linear regression. In these analyses, expression level was the
dependent variable and the two groups of individuals (either
nonagenarians vs. controls or offspring vs. controls) were included
in the model as a categorical variable together with age (in
offspring vs. controls only) and gender and their interaction as
covariates. To take into account dependencies within sibships,
robust standard errors were used, i.e. the variance was computed
from the between family variation. P-values were also based on
these robust standard errors. Analyses were performed using the
software package STATA/SE 11.0 (DPC Software, StataCorp
2009).
Analysis of healthy offspring
To further investigate the candidate genes, their expression level
was again tested for association with longevity, but only including
the offspring with most beneficial profile of seven published
longevity markers: a low level of non-fasted serum glucose (mmol/
L) [71,72], triglycerides (mmol/L) [73] and free triiodothyronine
levels (pmol/L) [74], a small ratio of total cholesterol (mmol/L)
over HDL cholesterol (mmol/L) [75,76], small low-density
lipoprotein (LDL) particle sizes (nm) [77], a high level of
adiponectin (mg/L) [26], and a low Framingham risk score
(FRS) which is based on the factors age, sex, total cholesterol level,
HDL cholesterol level, systolic blood pressure (mm/Hg), and
whether the person smokes [78]. The FRS is a well known test
reflecting the risk of cardiovascular disease over the course of 10
years.
All serum measurements were performed with fully automated
equipment. For glucose, triglycerides, total cholesterol, HDL-
cholesterol, adiponectin and free triiodothyronine, the Hitachi
Modular or the Cobas Integra 800, both from Roche, Almere, the
Netherlands were applied. CVs of these measurements were all
below 5%. Lipoprotein particle sizes have been analyzed in 165
families from the Leiden Longevity Study using a 400-MHz
proton NMR analyzer at LipoScience.
To select that subfraction of offspring with the highest
probability to age healthily and become long-lived because of
their metabolic risk profile in middle-age, we identified the
subjects, separately for men and women, within the lower 5% tail
of the distribution for glucose, triglycerides, free triiodothyronine,
ratio of total cholesterol over HDL cholesterol and the FRS.
Additionally we identified for LDL particle size and adiponectin
those subjects, separately for men and women, within the upper
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out of 332 from which gene expression levels of ASF1A and IL7R
was compared to the levels in 312 controls using linear regression.
In this analysis, expression level was the dependent variable and
the two groups of individuals (offspring vs. controls) were included
in the model as a categorical variable together with age and gender
and their interaction as covariates. To take into account
dependencies within sibships, robust standard errors were used,
i.e. the variance was computed from the between family variation.
P-values were also based on these robust standard errors. Analyses
were performed using the software package STATA/SE 11.0
(DPC Software, StataCorp 2009).
Supporting Information
Figure S1 Distribution of expression intensities of 2,953
age-related probes. The x-axis indicates average log2 expres-
sion intensities of all samples; the y-axis indicates the log2 fold
change between nonagenarians and controls. Black circles
represent all 45,164 probes; red filled dots represent the 2,953
age-related probes with a FDR#0.05.
(TIF)
Table S1 Significant gene expression changes with
chronological age and/or familial longevity. A total of
2,953 probes whose expression level changed significantly between
controls and long-lived nonagenarians (regression modeling with
FDR multiple testing correction) are shown. The table also
indicates the chromosomal location of the probe. ‘‘FC’’ indicates
the fold change between groups, a FC above 1 indicates increased
expression in nonagenarians compared to controls, and a FC
below 1 indicates decreased expression in nonagenarians com-
pared to controls. MULTIPLE indicates a probe annotated to
more than three chromosomal locations.
(XLS)
Table S2 GO terms found significantly differentially
expressed between nonagenarians and controls. Globalt-
est pathway analysis resulted in 109 Gene Ontology terms of
which the expression of the involved probes differed between long-
lived nonagenarians and controls (FWER#0.05). Gene Ontology
categories include biological process (BP), molecular function (MF)
and cellular component (CC).
(XLS)
Table S3 List of probes of which the gene expression
changes with age significantly differed between off-
spring and controls. A total of 360 probes whose expression
level changed significantly with age between offspring and controls
(regression modeling with FDR multiple testing correction) are
shown. ‘‘FC’’ indicates the fold change between offspring and
controls per 10 years; a FC above 1 indicates a larger slope of
expression as a function of age in offspring, a FC below 1 indicates
a larger slope of expression as a function of age in the controls.
MULTIPLE indicates a probe annotated to more than 3
chromosomal locations.
(XLS)
Table S4 RT-qPCR results of replication samples only.
RT-qPCR results of replication samples only are shown. ‘‘FC’’
indicates the fold change between groups; a FC above 1 indicates
an increase in expression and a FC below 1 indicates a decrease in
expression compared to the controls. ‘‘p’’ indicates the unadjusted
p values. Bold indicate p values are below the significant level of
0.05 after Bonferroni correction for multiple testing.
(DOC)
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